Is Gabapentin Bad for Your Kidneys?

Gabapentin does not appear to be directly toxic to healthy kidneys at normal doses, but the drug and your kidneys have an unusually intimate relationship. Your kidneys are the only way gabapentin leaves your body, so any decline in kidney function causes the drug to accumulate, sometimes to dangerous levels. A 2024 study also raised preliminary concerns that gabapentin itself might contribute to kidney function decline over time, making the picture more complicated than a simple yes or no.

Your Kidneys Are Gabapentin’s Only Exit

Most medications get broken down by the liver before being flushed out. Gabapentin is different. It passes through your system almost entirely unchanged and leaves exclusively through kidney filtration. There is no evidence of gabapentin being metabolized even in people with severely impaired kidneys.¹ This means your kidneys do all the heavy lifting. The rate at which your kidneys clear gabapentin tracks almost perfectly with your overall kidney filtration rate, making creatinine clearance a reliable predictor of how fast the drug will leave your body.²

There is even some genetic variation at play. Research on a transporter protein in the kidneys called OCTN1 found that people with one genetic variant clear gabapentin at a rate roughly equal to passive filtration, while people without that variant actively secrete the drug, clearing it faster.³ This means two people with identical kidney function could handle the same gabapentin dose somewhat differently based on genetics alone.

The Main Danger Is Drug Buildup, Not Direct Kidney Damage

Because gabapentin depends entirely on the kidneys, the drug accumulates when kidney function drops. Plasma concentrations climb, the drug sticks around longer, and side effects intensify. A study that grouped patients by kidney function found that those with chronic kidney disease (CKD) developed significantly higher blood levels of gabapentin than those with normal kidneys. Toxicity occurred in about 6% of patients with moderate impairment and in nearly 78% of patients with severe impairment.⁴ The toxic effects were worse as kidney function worsened, and older individuals with multiple health conditions were disproportionately affected.

What makes this particularly concerning is that gabapentin toxicity often goes unrecognized. In that same study, toxicity was initially suspected in only about 42% of symptomatic cases.⁴ The symptoms of gabapentin toxicity, which include extreme drowsiness, confusion, dizziness, unsteadiness, and involuntary muscle jerking, can mimic a stroke or other neurological emergencies. Clinicians may order brain scans and run stroke protocols before anyone thinks to check gabapentin levels, wasting time and resources while the actual cause goes untreated.

Doses Are Frequently Too High for Kidney Function

If the science is clear that gabapentin doses need to come down as kidney function declines, you might expect the problem to be rare in practice. It is not. A population-based study of over 74,000 CKD patients with new prescriptions for gabapentin or pregabalin found that roughly 41% started at doses above what guidelines recommend for impaired kidneys.⁵ In a hospital setting, a study of 286 patients found that about a third of gabapentin patients with reduced kidney function were prescribed doses above the manufacturer’s recommendation. Among those with the most severely impaired kidneys, almost half received inappropriately high doses.⁶

This overprescribing has real consequences. The same hospital study found a significant increase in recorded falls among patients with reduced kidney function.⁶ For older adults in particular, a fall can trigger a cascade of serious complications from hip fractures to prolonged hospital stays. The pattern suggests a systemic gap: prescribers are either unaware of a patient’s kidney function at the time of prescribing or not adjusting the dose downward as kidney function changes over time. Because kidney function can fluctuate, especially during hospitalization, a dose that was safe a month ago may not be safe today.

Can Gabapentin Actually Damage Kidneys Directly?

This is the question most people are really asking, and until recently the answer was a fairly confident “probably not.” Animal studies looking at kidney tissue after gabapentin exposure found no serious histological changes, suggesting the drug does not physically injure kidney cells at therapeutic doses.⁷ However, one long-term animal study did find a significant increase in creatinine levels in rats given gabapentin over an extended period, along with other biochemical changes, though these were partially reversible with protective supplements.⁸ Animal data does not translate directly to humans, but it hints that long-term use at higher doses may not be as benign to the kidneys as once assumed.

More provocatively, a 2024 study compared patients who started gabapentin with those who started pregabalin around the time of surgery. After matching for other factors, gabapentin use was associated with a 40% higher risk of kidney function decline compared to pregabalin, and a 46% higher risk of developing new CKD when people who already had the condition were excluded.⁹ This is a single observational study and does not prove that gabapentin caused the kidney decline. The perioperative setting introduces confounders like anesthesia, fluid shifts, and other nephrotoxic medications. Still, it is the kind of finding that warrants attention and follow-up research. Rates of acute kidney injury and death during hospitalization were similar between the two drugs, so whatever signal exists seems to be a longer-term, subtler effect rather than an acute insult.

In short, the evidence that gabapentin directly harms healthy kidneys is thin but no longer nonexistent. For most people taking standard doses with normal kidney function, this is not an immediate worry. For people already at risk for kidney problems, or those taking the drug long-term, it adds another reason to monitor kidney function periodically.

When Gabapentin Overdose Causes Acute Kidney Injury

There is one scenario where gabapentin unambiguously causes kidney damage, and that is massive overdose. A published case report described a patient who took a large gabapentin overdose and developed severe rhabdomyolysis, a condition where muscle tissue breaks down and floods the kidneys with a protein called myoglobin. The myoglobin caused acute tubular necrosis, which is direct destruction of the cells lining the kidney’s filtration tubes, and the patient needed dialysis to survive.¹⁰ This is rare and specific to overdose, but it is worth knowing about because gabapentin is sometimes perceived as entirely harmless, and that perception can lead to cavalier attitudes about extra doses or stockpiled pills.

Gabapentin toxicity in people already on dialysis also presents unique challenges. In a case involving a patient on peritoneal dialysis who developed gabapentin toxicity, continuous dialysis cycling over about 36 hours was needed to bring drug levels down to a safe range. Without functioning kidneys, the drug’s half-life can stretch to over 130 hours, meaning it takes days for levels to drop on their own.¹¹ This illustrates why gabapentin monitoring becomes critical in people with little or no kidney function. Routine drug-level monitoring is not usually recommended for gabapentin, but researchers have argued it should be considered for patients with CKD or those on dialysis.¹²

Gabapentin Is Actually Used to Treat Kidney Disease Symptoms

Here is the irony: gabapentin is not just a drug that kidney patients need to be careful with. It is also a drug that kidney patients actively benefit from. One of the most maddening symptoms of advanced kidney disease is uremic pruritus, a relentless itching that does not respond well to antihistamines or moisturizers. Gabapentin has become a go-to treatment for this condition. A systematic review of randomized controlled trials found that gabapentin significantly reduced itching severity compared to placebo, with the pooled analysis strongly favoring gabapentin.¹³

A qualitative review of seven studies covering 179 hemodialysis patients confirmed this: six of seven studies showed significant improvements in itch scores, with patients reporting major reductions on standard itch scales within three to eight weeks of treatment. Side effects like sleepiness and dizziness were common, though only a handful of patients stopped the drug because of them.¹⁴ The same benefits extend to restless legs syndrome, another frequent complaint in CKD patients. A study comparing dialysis patients with those managed without dialysis found that gabapentin reduced both itching and restless legs symptoms across both groups, though side effects were more common in the non-dialysis group.¹⁵

This means gabapentin occupies a peculiar double role in kidney disease: it is both a drug that demands extreme caution in dosing and one of the more effective treatments for symptoms that seriously affect quality of life. The key is dose adjustment, not avoidance.

How Dosing Changes With Kidney Function

For someone with normal kidneys, gabapentin doses for conditions like diabetic nerve pain can go up to about 2,400 mg per day. As kidney function drops, those numbers have to come down substantially. Guidelines for CKD patients recommend capping the total daily dose at about 1,400 mg when kidney filtration is moderately reduced, dropping to around 700 mg for more significant impairment, and going no higher than 300 mg for the most severely affected patients.¹⁶ For people on hemodialysis, a loading dose is typically given, and then smaller supplemental doses are given after each dialysis session because the machine removes a meaningful chunk of the drug. About 35% of a gabapentin dose gets pulled out during a typical dialysis session.¹⁷

One complication specific to dialysis patients: gabapentin blood levels tend to bounce upward by about 30% in the first two hours after a dialysis session ends, as the drug redistributes from tissues back into the bloodstream.¹⁷ This rebound effect means that even right after dialysis, when you might expect levels to be lowest, concentrations can temporarily spike. The practical takeaway is that dose timing matters, and patients on dialysis need closer follow-up than the typical gabapentin user.

Risks that are merely inconvenient in people with normal kidneys become more dangerous in advanced CKD. Myoclonus, the involuntary jerking of muscles, is one example. In people with normal kidney function, gabapentin-induced myoclonus is a nuisance. In advanced CKD and dialysis patients, it becomes more disabling and mandates stopping the drug.¹⁶

Drug Combinations That Raise the Stakes

Gabapentin’s risks do not exist in a vacuum. What else a person is taking matters significantly. A study of hospitalized patients with reduced kidney function found that concomitant use of opioids and psychiatric medications contributed to a higher rate of adverse events regardless of how impaired the kidneys were.⁶ This is relevant because gabapentin is frequently prescribed alongside opioids in pain management, and both drug classes cause sedation. When gabapentin levels are elevated due to impaired clearance, combining it with opioids creates compounding risks for excessive sedation, respiratory depression, and falls.

This combination is especially common in older adults, the same group most likely to have undiagnosed or worsening kidney function. The typical scenario is a patient who has been on gabapentin for chronic pain, develops CKD gradually over years, and never has their gabapentin dose adjusted. By the time symptoms appear, blood levels may be far above the therapeutic range. If opioids are part of the picture, the resulting sedation and confusion can be severe enough to prompt emergency department visits and hospitalizations.

Why Gabapentin Use Actually Increases as Kidneys Decline

You might expect doctors to prescribe gabapentin less often as kidney function worsens. The opposite appears to be true. A study of over 3,100 CKD patients found that gabapentinoid use climbed from about 6% in early-stage kidney disease to over 9% in advanced stages.¹⁸ The reason is straightforward: as kidney disease progresses, other common painkillers become less safe. NSAIDs can worsen kidney function and raise blood pressure. Opioids carry their own accumulation risks in kidney disease. Gabapentin often looks like the least bad option for nerve pain, itching, or restless legs, and in many cases it genuinely is the best available choice. But the very patients who need it most are also the ones most vulnerable to its buildup, which is why dose adjustment and monitoring become essential rather than optional.

The tension between gabapentin’s usefulness and its risks in kidney disease patients is not going to be resolved by simply avoiding the drug. For many people with advanced CKD, the symptoms gabapentin treats are severe enough to justify the risks, provided the dose is right and someone is paying attention. The real failure is not prescribing gabapentin to kidney patients. It is prescribing it at the wrong dose and then forgetting to check whether the kidneys can still handle it.